Holen Sie sich die Stockscreener-App
1.21
0.82%
-0.01
Schlusskurs vom Vortag:
$1.22
Offen:
$1.21
24-Stunden-Volumen:
326
Relative Volume:
0.00
Marktkapitalisierung:
$50.67M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-11.24M
KGV:
-1.589
EPS:
-0.7615
Netto-Cashflow:
$-4.79M
1W Leistung:
-0.82%
1M Leistung:
+2.54%
6M Leistung:
-27.11%
1J Leistung:
+25.00%
1-Tages-Spanne:
$1.21
$1.21
1-Wochen-Bereich:
$1.1206
$1.22
52-Wochen-Spanne:
$0.73
$2.45
Mira Pharmaceuticals Inc Stock (MIRA) Company Profile
Firmenname
Mira Pharmaceuticals Inc
Sektor
Telefon
813-369-5150
Adresse
1200 BRICKELL AVENUE, MIAMI
Compare MIRA vs LLY, JNJ, ABBV, AZN, NVS
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MIRA
Mira Pharmaceuticals Inc
|
1.21 | 48.58M | 0 | -11.24M | -4.79M | -0.7615 |
|
LLY
Lilly Eli Co
|
992.93 | 894.20B | 65.18B | 20.64B | 5.96B | 22.59 |
|
JNJ
Johnson Johnson
|
242.10 | 587.32B | 94.19B | 26.80B | 19.70B | 11.05 |
|
ABBV
Abbvie Inc
|
226.39 | 401.39B | 61.16B | 4.19B | 17.82B | 2.3614 |
|
AZN
Astrazeneca Plc
|
192.81 | 302.39B | 58.80B | 10.24B | 8.98B | 3.2788 |
|
NVS
Novartis Ag Adr
|
155.43 | 308.34B | 54.72B | 14.02B | 15.32B | 7.1855 |
Mira Pharmaceuticals Inc Aktie (MIRA) Neueste Nachrichten
MIRA Pharmaceuticals completes dosing in Ketamir-2 Phase I trial - MSN
Wall Street Recap: What are MIRA Pharmaceuticals Incs recent SEC filings showing2025 Historical Comparison & Weekly High Return Stock Forecasts - baoquankhu1.vn
Winners Losers: Can MIRA Pharmaceuticals Inc deliver alphaQuarterly Risk Review & Step-by-Step Trade Execution Guides - baoquankhu1.vn
MIRA completes Phase 1 trial of oral NMDA drug Ketamir-2 - Investing.com
MIRA Pharmaceuticals Completes Phase 1 Dosing of Ketamir-2 - ACCESS Newswire
MIRA tests oral Ketamir-2 for chemo nerve pain after safe Phase 1 - Stock Titan
MIRA Pharmaceuticals, Inc. (MIRA) Competitors - Meyka
MIRA Completes Phase 1 Trial of Ketamir-2 Therapy - TipRanks
Mira Pharmaceuticals Inc completes phase 1 dosing of Ketamir-2SEC filing - marketscreener.com
Mira Pharmaceuticals IncCompletes Phase 1 Dosing Of Ketamir-2SEC Filing - TradingView
MIRA Pharmaceuticals (NASDAQ: MIRA) finishes Ketamir-2 Phase 1 dosing with encouraging safety - Stock Titan
MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) Short Interest Up 29.4% in February - MarketBeat
Ideas Watch: How does MIRA Pharmaceuticals Inc compare to its peersPortfolio Risk Summary & Verified Momentum Stock Watchlist - baoquankhu1.vn
Risk Analysis: What is the Moat Score of MIRA Pharmaceuticals IncWeekly Earnings Recap & Real-Time Price Movement Reports - baoquankhu1.vn
MIRA Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
MIRA Pharmaceuticals Inc. (MIRA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Aug Summary: What are MIRA Pharmaceuticals Incs recent SEC filings showingJuly 2025 Opening Moves & Safe Capital Investment Plans - baoquankhu1.vn
MIRA Pharmaceuticals board approves SKNY Pharmaceuticals acquisition; combined value tops $60M - MSN
What is MIRA Pharmaceuticals Inc. s revenue forecastEarnings Overview Report & Daily Price Action Insights - mfd.ru
MIRA PE Ratio & Valuation, Is MIRA Overvalued - Intellectia AI
What are MIRA Pharmaceuticals Inc.’s recent SEC filings showingPortfolio Value Summary & High Conviction Buy Zone Alerts - mfd.ru
How does MIRA Pharmaceuticals Inc. compare to its peersJuly 2025 PreEarnings & Daily Technical Stock Forecast Reports - mfd.ru
Weekly Roundup on the Cannabis Sector & Psychedelic Sector - marketexclusive.com
MIRA Pharmaceuticals (NASDAQ:MIRA) Shares Down 6.6%Time to Sell? - MarketBeat
MIRA Pharmaceuticals (NASDAQ:MIRA) Stock Price Down 6.6%Time to Sell? - MarketBeat
Bear Alert: How is GIGGW managing supply chain issues2025 Big Picture & Long Hold Capital Preservation Plans - baoquankhu1.vn
MIRA Pharmaceuticals initiates final dosing in phase 1 trial of Ketamir-2 - Investing.com Nigeria
MIRA Pharmaceuticals initiates final dosing in phase 1 trial of Ketamir-2 By Investing.com - Investing.com South Africa
MIRA Pharmaceuticals Initiates Final Cohort of Ketamir-2 Phase 1 Clinical Study as Company Prepares for Phase 2a Study - Rutland Herald
Cancer nerve pain has no approved drugs. Oral trial nears first-phase finish - Stock Titan
MIRA Pharmaceuticals Advances Ketamir-2 Phase 1 to Final Cohort - TipRanks
MIRA Pharmaceuticals Announces Favorable Topline Results from Phase 1 SAD Study of Oral Ketamir-2, a Next-Generation Non-Scheduled Ketamine Analog - Pensacola News Journal
Value Recap: What is the Moat Score of MIRA Pharmaceuticals IncWeekly Trade Summary & Real-Time Volume Trigger Notifications - baoquankhu1.vn
Can MIRA Pharmaceuticals Inc. stock deliver consistent earnings growthGlobal Markets & Safe Entry Zone Identification - bollywoodhelpline.com
MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) Sees Significant Growth in Short Interest - Defense World
Nasdaq Moves: Is DiaMedica Therapeutics Inc a cyclical or defensive stockMarket Performance Summary & Expert Verified Movement Alerts - baoquankhu1.vn
Aug Big Picture: How does MIRA Pharmaceuticals Inc compare to its peersGap Down & Detailed Earnings Play Strategies - baoquankhu1.vn
Will MIRA Pharmaceuticals Inc. stock maintain dividend yieldWide Width Options & HOKA model picks for your routine - Улправда
Trendlines Suggest Garment Mantra Lifestyle Limited May Bottom Out Soon - Bollywood Helpline
2026 world cup usa national team qualification midfield leaders build up play winner prediction guideJuly 2025 Volume & Low Volatility Stock Recommendations - Улправда
2026 world cup mexico qualification playmakers low block knockout prediction analysis - Улправда
2026 world cup canada qualification match preview insightsIndex Update & Fast Entry and Exit Trade Plans - Улправда
Quarterly Risk: Will MIRA Pharmaceuticals Inc stock gain from strong economyJobs Report & Real-Time Buy Signal Alerts - Bộ Nội Vụ
MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) Short Interest Update - MarketBeat
Resistance Break Could Fuel Unichem Laboratories Limited RallyEarnings Beat Highlights & Maximize Gains Professionally - Bollywood Helpline
Mira Pharmaceuticals approves CEO incentive awards including SKNY acquisition bonus By Investing.com - Investing.com South Africa
Mira Pharmaceuticals approves CEO incentive awards including SKNY acquisition bonus - Investing.com
Will MIRA Pharmaceuticals Inc. stock gain from strong economyJuly 2025 Recap & Fast Moving Stock Trade Plans - Bölüm Sonu Canavarı
Is MIRA Pharmaceuticals Inc. stock a safe investment in uncertain markets2025 Price Targets & Fast Entry Momentum Trade Alerts - Улправда
MIRA Pharmaceuticals (MIRA) details 2025 CEO bonuses and equity awards - Stock Titan
Can MIRA Pharmaceuticals Inc. stock beat analyst upgradesOptions Play & Weekly Setup with ROI Potential - Улправда
Finanzdaten der Mira Pharmaceuticals Inc-Aktie (MIRA)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.59%
0.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):